Yin Yongjun, Wang Yilan, Liu Ying, Wang Fei, Wang Zhenxing
Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan, 610075, China.
Heliyon. 2024 Jul 14;10(14):e34572. doi: 10.1016/j.heliyon.2024.e34572. eCollection 2024 Jul 30.
Jinshuibao capsules has been utilized in treating stable chronic obstructive pulmonary disease (COPD) for a long time. While the evidence-based evidence and network pharmacology to clarify the therapeutic efficacy and pharmacological mechanisms of Jinshuibao capsules have remained elusive.
Integrating evidence-based medicine and network pharmacology to explain the therapeutic efficacy and pharmacological mechanisms of Jinshuibao capsules for stable COPD.
Cochrane Library, Web of Science, EMBASE, PubMed, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, VIP Information Resource Integration Service Platform (CQVIP), and China Biomedicine (SinoMed) databases were searched. Studies were selected according to the inclusion and exclusion criteria. Statistical analysis was performed using the RevMan 5.3 software (Cochrane, London, UK). In network pharmacology, components of Jinshuibao capsules were screened, stable COPD-related genes were then identified and the 'component-target-pathway' network constructed.
Meta-analysis revealed that Jinshuibao capsules exerts therapeutic effects on stable COPD by increasing the levels of FEV1% pred, FEV1/FVC ratio, FEV1, FVC, and PaO2 while decreasing the level of PaCO2. In addition, Jinshuibao capsules could effectively increase the levels of CD3, CD4/CD8 ratio, Th17/Treg ratio, and SOD while reduce the levels of IL-8 and TNF-α. Network pharmacology identified 22 active compounds and 419 intersection gene targets. AKT1, SRC, MAPK1, STAT3, and MAPK3 were top 5 key target proteins. Besides, 20 potential pathways of Jinshuibao capsules on stable COPD were identified, like endocrine resistance, AGE-RAGE signaling pathway in diabetic complications, and chemical carcinogenesis-receptor activation.
Jinshuibao capsules could positively influence patients with stable COPD, while the efficacy and safety of Jinshuibao capsules in the treatment of COPD could not be reliably confirmed. These findings suggest that Jinshuibao capsules exerts effect on stable COPD through multi-target, multi-component and multi-pathway mechanism. Future studies may explore the active components of Jinshuibao capsules.
金水宝胶囊长期用于治疗稳定期慢性阻塞性肺疾病（COPD）。然而，阐明金水宝胶囊治疗效果和药理机制的循证证据和网络药理学研究仍不明确。
整合循证医学和网络药理学，以解释金水宝胶囊治疗稳定期COPD的疗效和药理机制。
检索Cochrane图书馆、Web of Science、EMBASE、PubMed、中国知网（CNKI）、万方数据知识服务平台、维普资讯资源整合服务平台（CQVIP）和中国生物医学文献数据库（SinoMed）。根据纳入和排除标准选择研究。使用RevMan 5.3软件（英国伦敦Cochrane公司）进行统计分析。在网络药理学方面，筛选金水宝胶囊的成分，然后鉴定稳定期COPD相关基因，并构建“成分-靶点-通路”网络。
Meta分析显示，金水宝胶囊通过提高FEV1%预计值、FEV１/FVC比值、FEV1、FVC和PaO2水平，同时降低PaCO2水平，对稳定期COPD发挥治疗作用。此外，金水宝胶囊可有效提高CD3、CD4/CD8比值、Th17/Treg比值和SOD水平，同时降低IL-8和TNF-α水平。网络药理学鉴定出22种活性化合物和419个交集基因靶点。AKT1、SRC、MAPK1、STAT3和MAPK3是前5个关键靶蛋白。此外，还确定了金水宝胶囊治疗稳定期COPD的20条潜在通路，如内分泌抵抗、糖尿病并发症中的AGE-RAGE信号通路和化学致癌-受体激活。
金水宝胶囊对稳定期COPD患者有积极影响，但其治疗COPD的疗效和安全性尚不能得到可靠证实。这些发现表明，金水宝胶囊通过多靶点、多成分和多通路机制对稳定期COPD发挥作用。未来研究可探索金水宝胶囊的活性成分。
